Kommentar

• Literatur

• 1 Mair-Jenkins J, Saavedra-Campos M, Baillie JK. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211: 80-90
• 2 Duan K, Liu B, Li C. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117: 9490-9496
• 3 Shen C, Wang Z, Zhao F. et al. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA 2020; 323: 1582-1589
• 4 Bundesministerium für Gesundheit. Bekanntmachung nach § 79 Absatz 5 des Arzneimittelgesetzes vom 26. Februar 2020. Köln: Bundesanzeigerverlag; 2020
• 5 FDA. Recommendations for Investigational COVID-19 Convalescent Plasma: 2020. Im Internet (Stand: 14.07.2020): https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma
• 6 Li L, Zhang W, Hu Y. et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 2020;